#NOVONORDISK News

FEED

Ozempic maker Novo Nordisk facing pressure as study finds $1000 appetite suppressant can be made for just $5

fortune.com Ozempic could be profitably produced for less than $5 a month even as maker Novo Nordisk A/S charges almost $1,000 in the US, according to a study that revives questions…

Novo Nordisk Under Fire, Post-Ozempic Study

tipranks.com Healthcare major Novo Nordisk (NYSE:NVO) has come under fire following a study indicating that NVO’s popular diabetes drug Ozempic can be manufactu...

Insurance Coverage For Weight Loss Drugs

benzinga.com Some major U.S. health insurers, including CVS Health Inc CVS, Elevance Health Inc ELV and Kaiser Permanente, will start reimbursing for Novo Nordisk A/S’s NVO Wegovy, a…

Study: ‘gamechanger’ diabetes drugs cost up to 400 times more than needed

theguardian.com Drug companies are pricing diabetes medicines at almost 400 times the level necessary to make a profit, according to a new study. Researchers said it would also be possible…

3 Healthcare Stocks to Buy From 3 of the Best Actively Managed Funds

investorplace.com These three healthcare stocks to buy all have excellent businesses published an article in February discussing cheap healthcare stocks to buy, noting comments from Janus…

7 Stocks That Will Drive the Weight Loss Drugs Market

marketbeat.com The global obesity epidemic has reached unprecedented proportions, causing severe health consequences and placing an immense economic burden on healthcare systems.…

Prediction: This Will Be the Next "Magnificent Seven" Stock

finance.yahoo.com The "Magnificent Seven" originally made the headlines as a Western back in 1960, but in recent times, it's entered the investing world. Bank of America analyst Michael…

Eli Lilly, IBD Stock Of The Day, Jumps Entry As Obesity Space Heats

investors.com stock is Wednesday's IBD Stock Of The Day. Shares are forming a flat base as competition mounts for Lilly's weight-loss drug, Zepbound. This week, Viking Therapeutics (VKTX)…

Novo Nordisk's $1,000 diabetes drug Ozempic can be made for less than $5 a month, study suggests

cnbc.com The blockbuster diabetes drug Ozempic could be manufactured for less than $5 a month, even as Novo Nordisk charges close to $1,000 per month for the injection in the U.S.…

Altimmune says weight loss drug minimized muscle loss in trial results that may set it apart

cnbc.com Altimmune on Wednesday said its experimental drug helped patients shed weight, but also minimized the loss of muscle mass in a mid-stage trial, a finding that could…

The 2025 Double: 3 Stocks Poised to Deliver 100% Gains in Just 12 Months

investorplace.com These stocks have legitimate chances to double over the coming 12 months Wise investors know that it isn’t prudent to chase 100% returns within a period as short as 12…

The Surprising Way You Can Lower Employee Stress

inc.com Ozempic maker Novo Nordisk says their employees have incredibly low stress levels. Let's dive into those numbers -- and how you can reduce stress in your business.

Here's 1 Huge New Reason to Buy Madrigal Pharmaceuticals Stock

finance.yahoo.com While Madrigal Pharmaceuticals' (NASDAQ: MDGL) shares have gained only about 5% in the past 12 months, things are looking up for the midcap biotech. With its triumphant…

Dexcom Stock Shows Market Leadership, Gets Rating Upgrade. Prognosis Good

investors.com faced down what some thought was an existential threat. The prognosis is good; it's recovering nicely. Dexcom stock just topped the buy point of a cup base and it got an…

Krispy Kreme-McDonald's Deal Spikes Insulin Stock Interest: 'We're About To Cash In On The Aftermath'

benzinga.com Shares of Krispy Kreme Inc DNUT have surged following the company’s announcement of an expanded national partnership with McDonald's Corp MCD. McDonald’s customers will now…

Healthy Returns: Drugmakers are capping inhaler prices at $35 in a win for some patients

cnbc.com Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good afternoon! Inhalers will soon get a whole lot cheaper for some…

Viking Therapeutics stock rises on positive oral obesity drug Phase 1 data

finance.yahoo.com reported positive early phase results for its oral weight-loss drug Tuesday, sending the stock soaring more than 25% in early trading. Viking said its Phase 1 results, which…

3 Stocks to Buy for the Next Bull Run: March 2024

investorplace.com These securities are likely to see big gains in coming months as the market rally continues As we approach the end of the year’s first quarter, the stock market has enjoyed…

Viking Surges After Weight-Loss Pill — A Rival To Novo, Lilly

investors.com Viking stock gapped up Tuesday after the biotech company's oral weight-loss drug — a potential rival to Eli Lilly (LLY) and Novo Nordisk (NVO) — beat expectations in a…

Viking Therapeutics Stock Rises After Data on Obesity Pill

barrons.com Two recent sets of data from Viking Therapeutics set it up as a serious challenger to Eli Lilly and Novo Nordisk.

Viking Therapeutics stock rises on positive Phase 1 weight-loss pill data

aol.com reported positive early phase results for its oral weight-loss drug Tuesday, sending the stock soaring more than 25% in early trading. Viking said its Phase 1 results, which…

Viking Therapeutics' weight-loss tablet shows promise in small study

finance.yahoo.com Viking Therapeutics' experimental tablet reduced weight by as much as 3.3% when tested in volunteers enrolled in a small early-stage trial, meeting Wall Street expectations…

Adobe Launches Real-Time CDP Collaboration With Partner NBCUniversal

mediapost.com Adobe introduced a real-time customer data platform (CDP) collaboration feature for advertisers and publishers on Tuesday that will help them collaborate to find and…

Viking Therapeutics stock jumps more than 25% on promising weight loss pill data

cnbc.com Viking Therapeutics shares jumped more than 25% on Tuesday after the company said its experimental weight loss pill showed positive results in a small study and will enter…

Up 68% in 1 Year, Is Novo Nordisk Stock Still a Buy?

barchart.com Novo Nordisk is a blue-chip healthcare stock that has delivered game-changing returns to shareholders in the past two decades. Is NVO stock still a good buy?

Weight loss drugs firm expands into heart disease treatment

euronews.com The Nova Nordisk deal is due to be wrapped up in the second quarter of this year. It will help establish the maker of Wegovy and Ozempic in the cardiovascular treatment…

Best Obesity Drug Stock: Eli Lilly, Novo Nordisk, or Viking Therapeutics?

finance.yahoo.com Some investors might remember the obesity drugs developed by Arena Pharmaceuticals and Vivus Pharmaceuticals several years ago. They'll probably also recall that the initial…

Column: A Trump judge slaps down Big Pharma's attack on Biden's drug price cuts

latimes.com President Biden speaks during an event in August marking the one-year anniversary of the Inflation Reduction Act, which authorized Medicare to negotiate drug prices. The…

Wegovy maker Novo Nordisk struck a deal to buy heart-disease-therapeutics developer Cardior Pharmaceuticals for up to the equivalent of $1.11 billion

wsj.com Wegovy maker Novo Nordisk struck a deal to buy heart-disease-therapeutics developer Cardior Pharmaceuticals for up to the equivalent of $1.11 billion.

Uncovering Hidden Gems: 1 AI-Powered Healthcare Stock Set to Dominate the Market

finance.yahoo.com Artificial intelligence (AI) and innovative pharmaceutical treatments in the weight-loss market have brought newfound interest to the technology and healthcare sectors. One…

Apple, Intel, Tesla and United Airlines fall premarket; Walt Disney rises

investing.com Investing.com -- U.S. slipped lower Monday, consolidating at the start of a holiday-shortened week ahead of the release of key inflation data and several Fed speakers. Here…

Novo Nordisk targets heart disease in $1.1 billion deal

marketwatch.com Novo Nordisk, the Danish pharmaceutical whose market cap has swelled due to popular weight loss drugs, on Monday announced it was making an acquisition targeting…

Novo Nordisk and Eli Lilly May Finally Have Some Real Competition

finance.yahoo.com One of the biggest themes in the pharmaceutical market right now is weight-loss treatments. Demand is off the charts for medications including Ozempic, Rybelsus, Saxenda,…

Novo Nordisk Expands Cardio Push with Cardior Buy

wsj.com Novo Nordisk is buying Cardior Pharmaceuticals for around $1 billion as it strengthens its pipeline of drugs to treat cardiovascular disease and expand into areas outside of…

The weight loss drug race has Amgen coming for Novo Nordisk and Eli Lilly

qz.com Biotech company Amgen is testing a new injectable weight loss treatment as it looks to beat other drugmakers to the punch. Amgen’s new monthly injection treatment, MariTide,…

Nvidia's AI Tech Part of Novo Nordisk's New Supercomputer

marketbeat.com Two of the year’s biggest investment themes, artificial intelligence and anti-obesity drugs, are finally meeting up, as Novo Nordisk A/S NYSE: NVO and Nvidia Corp. NASDAQ:…

Amgen wants in on the booming weight loss drug market

cnbc.com Amgen is taking a new approach as it tries to stand out in a crowded field of drugmakers racing to develop the next blockbuster weight loss drug. The biotech company is…

Who was the best CEO of 2023?

economist.com It has been a tricky year atop the corporate ladder. Sluggish growth in many markets has set bosses scrambling to rein in costs just as inflation has spurred their workers…

Here's how much people are willing to spend on weight loss drugs, according to a new survey

cnbc.com Demand for weight loss drugs is booming in the U.S. despite their limited insurance coverage and roughly $1,000 monthly price tags before discounts. But some patients are…

Will Pfizer Be a Trillion-Dollar Stock by 2035?

finance.yahoo.com Some investors look at Pfizer (NYSE: PFE) as a has-been. That's understandable in some ways. Sales for the company's once-formidable COVID-19 franchise have tanked. So have…

Why FOMO Is Fueling Nvidia Stock

vanityfair.com In mid-October 2022, Nvidia, the AI chipmaker, was worth around $280 billion. Less than a year and a half later, the company is worth $2.2 trillion. Yes, that’s an…

Hot Stocks: The 3 Best Opportunities for Investing in Weight Loss Drugs

investorplace.com For investors looking to play the weight loss drug stocks space, here are three companies to watch closely Prescription weight loss drugs, like GLP-1 agonists and orlistat,…

Medicare plans can now cover Wegovy for patients at risk of heart disease

npr.org Medicare plans can now cover Wegovy for patients at risk of heart disease For the first time, Medicare will allow coverage of one of the new blockbuster weight-loss drugs…

How Are Obesity Drugs And Nvidia Related? Success Of Ozempic, Wegovy Propels Novo Nordisk Foundation To Fund Nvidia-Powered AI Supercomputer For Faster Drug…

benzinga.com Novo Nordisk A/S NVO, the maker of popular diabetes and weight loss drugs like Ozempic and Wegovy, is delving into artificial intelligence. Backed by the Novo Nordisk…

Medicare can now cover certain weight loss drugs in a big step for patients

cnbc.com Boxes of Wegovy made by Novo Nordisk are seen at a pharmacy in London, Britain March 8, 2024. Medicare can start covering certain weight loss drugs for the first time — as…

Weight loss drug could be available to millions of Americans

newsweek.com Wegovy, a drug which has seen massive demand in recent years due its weight loss properties, will now be made available to Medicare patients to help reduce their risk of…

Ozempic Users Speak Out Over Side Effects, Lawsuits Against Novo Nordisk And Eli Lilly Surge

benzinga.com Scores of patients are reportedly taking legal action against pharmaceutical giants Eli Lilly And Co LLY and Novo Nordisk A/S NVS, alleging severe complications after taking…

Ozempic maker Novo Nordisk has a new goal for its leadership team: Make sure no more than 10% of your staff are stressed

aol.com Workers today have much to be stressed out about; Geopolitical tensions are dominating their social media feeds, the cost of living is spiraling and the property market…

You could pay for Wegovy with Medicare, but there’s a catch

fortune.com Medicare can pay for the popular weight-loss drug Wegovy — as long as the patients using it also have heart disease and need to reduce the risk of future heart attacks,…

Medicare plans can cover Wegovy for patients with heart conditions

washingtonpost.com Medicare plans can cover the popular weight-loss drug Wegovy to treat seniors with a history of cardiovascular disease, officials said Thursday, a move that could…

This Under-the-Radar Stock Just Hit a Major Milestone: Time to Buy?

finance.yahoo.com Breakthroughs in the biotech industry sometimes come from relatively small drugmakers. Competing with the largest companies in significantly crowded areas, such as oncology,…

Medicare Will Cover Weight-Loss Drugs

investors.com Shares of Novo Nordisk (NVO) and Eli Lilly (LLY) dipped despite a Thursday report that Medicare could pay for weight-loss drugs for some members. According to the Wall…

Hot Stocks: The 3 Best Opportunities for Investing in Biotech

investorplace.com Find out which biotech stocks have explosive potential for the year ahead! When it comes to risk vs. reward in the stock market, the biotech sector has one of the highest…

Medicare can pay for obesity drugs like Wegovy in certain heart patients

apnews.com Medicare can pay for the popular weight-loss drug Wegovy — as long as the patients using it also have heart disease and need to reduce the risk of future heart attacks,…

The Entire Business World on a Single Page. Free to Use →